# Teri F. Willey

> Teri F. Willey is a funding round investor at IU Ventures backing Biotechnology and Therapeutics. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [IU Ventures](https://shizune.co/investors/profile/iu-ventures)
- Location: Cold Spring Harbor, United States
- Total investments: 6
- Last investment: Nov 2025
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/pub/teri-f-willey/4/865/5b

Teri F. Willey is a funding round investor at IU Ventures in Cold Spring Harbor focused on Biotechnology and Therapeutics. Teri F. Willey is the Managing Director at IU Ventures. Teri F. Willey attended University of Idaho.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 50% |
| Therapeutics | 2 | 33% |
| Apps | 1 | 17% |
| SaaS | 1 | 17% |
| Legal | 1 | 17% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 2 | 33% |
| Seed | 1 | 17% |
| Series B | 1 | 17% |
| Convertible Note | 1 | 17% |
| Venture - Series Unknown | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 50% |
| Canada | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SeraGene Therapeutics | SeraGene Therapeutics is a biotechnology company that offers treatment for coagulation disorders through nanomedicine technologies and RNA. |  | Seed | Nov 19, 2025 |  |
| Confluence Pharmaceuticals | Confluence Pharmaceuticals is developing novel therapeutic medications for neurological development disorders. The company's current focus is advancing a novel drug discovery that improves social and communication impairments for individuals with Autism Spectrum Disorders and Fragile X Syndrome. | $200K | Venture - Series Unknown | Jun 17, 2022 |  |
| Confluence Pharmaceuticals | Confluence Pharmaceuticals is developing novel therapeutic medications for neurological development disorders. The company's current focus is advancing a novel drug discovery that improves social and communication impairments for individuals with Autism Spectrum Disorders and Fragile X Syndrome. | $100K |  | Dec 02, 2020 |  |
| Rubicon Genomics | Rubicon Genomics was founded in 2000 by two University of Michigan faculty members, Dr. John Langmore and Dr. Vladimir Makarov, who wanted to advance the translation of human genetics “laboratory knowledge” into practical medicine applications. The founders also decided to maintain the company’s roots in Michigan with a commitment to supporting theMichigan economy.Today, Rubicon Genomics is a privately held company located in Ann Arbor, Michigan and employs 20 administrative and technical staff. Our innovative products combined with our strategic partnerships have established the company as a leader in pre-analytical amplification technologies that "break the sample barriers" for our customers. Rubicon sells its products into the research and commercial markets directly and through distributors | $3.5M | Series B |  |  |
| Confluence Pharmaceuticals | Confluence Pharmaceuticals is developing novel therapeutic medications for neurological development disorders. The company's current focus is advancing a novel drug discovery that improves social and communication impairments for individuals with Autism Spectrum Disorders and Fragile X Syndrome. | $100K | Convertible Note |  |  |
| Doxly | Doxly develops transaction-management software for law firms. It was built with one simple vision: transform the archaic, chaotic process of managing legal transactions into a streamlined, efficient process. Built by lawyers, for lawyers, the Doxly platform exists to remove frustrations inherent in legal transactions. Doxly helps lawyers deliverbetter client experiences while building stronger practices. Doxly began operation in 2016. It has its headquarters in Indianapolis in Indiana. | $250K |  |  |  |

6 of 6 investments shown.

## Co-investors
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 1 deal together
- [Blue Owl](https://shizune.co/investors/profile/blue-owl-e2cf) — VC Fund, 1 deal together
- [Boxer Capital](https://shizune.co/investors/profile/boxer-capital) — VC Fund, 1 deal together
- [Commodore Capital](https://shizune.co/investors/profile/commodore-capital) — VC Fund, 1 deal together
- [Deep Track Capital](https://shizune.co/investors/profile/deep-track-capital) — VC Fund, 1 deal together
- [Foresite Capital](https://shizune.co/investors/profile/foresite-capital) — VC Fund, 1 deal together

## About IU Ventures

VC Fund · Bloomington, United States

IU Ventures is affiliated with Indiana University focusing on assisting IU students, faculty, staff, and alums in new venture opportunities.

5 contacts available at IU Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Jonathan Barada | Vice President - Engagement | https://shizune.co/investors/profile/jonathan-barada |
| Teri F. Willey | Managing Director | https://shizune.co/investors/profile/teri-f-willey |
| Adam Sobol | Shoebox Fund Investment Committee Member | https://shizune.co/investors/profile/adam-sobol |
| Jason Wadler | Member/IU Angels | https://shizune.co/investors/profile/jason-wadler |
| Ken Green | Managing Director | https://shizune.co/investors/profile/ken-green |

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Teri F. Willey invest in?

Teri F. Willey invests primarily in Biotechnology, Therapeutics and Apps startups, most often at Funding Round and Seed stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Teri F. Willey last invest?

The most recent investment recorded for Teri F. Willey closed in Nov 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co